论文部分内容阅读
[目的]研究枸椽酸莫沙比利分散片联合雷贝拉唑钠肠溶片治疗功能性消化不良(FD)的疗效。[方法]将140例FD患者随机分为A(枸橼酸莫沙必利分散片)、B(雷贝拉唑钠肠溶片)、C(枸橼酸莫沙必利分散片联合雷贝拉唑钠肠溶片)、D(安慰剂)组。各组用药2周,观察患者临床症状好转率与不良反应发生率。[结果]A、B组均可使部分患者症状好转,与D组比较差异无统计学意义(P<0.05),而C组能使更多患者受益,与A、B组比较差异有统计学意义(P<0.01)。各组在使用药物2周时均能得到比1周时更好的效果。各组在用药过程中均无严重不良反应发生。[结论]枸橼酸莫沙比利联合雷贝拉唑钠肠溶片治疗FD安全有效。
[Objective] To study the efficacy of mosapride citrate dispersible tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of functional dyspepsia (FD). [Method] 140 patients with FD were randomly divided into A (mosapride citrate dispersible tablets), B (rabeprazole sodium enteric-coated tablets), C (mosapride citrate tablets combined with Rebebe Razo sodium enteric-coated tablets), D (placebo) group. Each group was treated for 2 weeks to observe the improvement rate of clinical symptoms and the incidence of adverse reactions in patients. [Results] The symptoms of some patients improved in group A and group B, and there was no significant difference between group A and group B (P <0.05), while group C could benefit more patients. There were statistically significant differences between group A and group B Significance (P <0.01). Each group was able to get a better result than the first week when using the medicine for two weeks. Each group in the course of medication without serious adverse reactions. [Conclusion] mosapride citrate combined with rabeprazole sodium enteric-coated tablets in the treatment of FD is safe and effective.